ADCT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors...

Stats
Today's Volume	1.17M
Average Volume	615 080
Market Cap	356.10M
EPS	$0 ( 2024-05-06 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.550
ATR14	$0.00800 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-08	Redmile Group, Llc	Buy	8 163 265	Pre-Funded Warrants
2024-05-08	Redmile Group, Llc	Buy	6 107 181	Pre-Funded Warrants
2024-05-07	Mallik Ameet	Sell	29 731	Common Shares
2024-01-03	Redmile Group, Llc	Sell	59 986	Cash-settled Swaps
2024-02-01	Redmile Group, Llc	Sell	19 700	Cash-settled Swaps

INSIDER POWER
58.03
Last 79 transactions
Buy: 16 087 938 \| Sell: 5 200 810

Volume Correlation

Long: 0.06 (neutral)

Short: -0.76 (moderate negative)

Signal:(40.675) Neutral

ADC Therapeutics SA Correlation

10 Most Positive Correlations
PGTI	0.961
ESMT	0.961
IHTA	0.953
AYX	0.95
NEWR	0.948
K	0.945
IHC	0.942
NKX	0.942
JWN	0.941
TCN	0.939

10 Most Negative Correlations
FLRT	-0.949
CANE	-0.944
SLB	-0.944
OII	-0.943
NVVE	-0.942
IEZ	-0.94
OIH	-0.937
WHD	-0.937
HAL	-0.935
FNGD	-0.935

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ADC Therapeutics SA Correlation - Currency/Commodity

0.45
( neutral )

0.43
( neutral )

0.00
( neutral )

0.06
( neutral )

-0.47
( neutral )

ADC Therapeutics SA Financials

Annual	2023
Revenue:	$69.56M
Gross Profit:	$67.03M (96.36 %)
EPS:	$-2.94

FY	2023
Revenue:	$69.56M
Gross Profit:	$67.03M (96.36 %)
EPS:	$-2.94

FY	2022
Revenue:	$209.91M
Gross Profit:	$205.33M (97.82 %)
EPS:	$-1.990

FY	2021
Revenue:	$33.92M
Gross Profit:	$32.52M (95.89 %)
EPS:	$-3.52

Financial Reports:

No articles found.

ADC Therapeutics SA

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.